Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia

American Journal of Cardiology

Volumn 82, Issue 12, 1998, Pages 1489-1495

  Mabuchi, Hiroshi ^a   Koizumi, Junji ^b   Shimizu, Masami ^b   Kajinami, Kouji ^b   Miyamoto, Susumu ^b   Ueda, Kousei ^b   Takegoshi, Tadayoshi ^b  

^a KANAZAWA UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HYPOCHOLESTEROLEMIC AGENT;

APHERESIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CORONARY RISK; DISEASE SEVERITY; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT OUTCOME;

AGED; ANTICHOLESTEREMIC AGENTS; BLOOD COMPONENT REMOVAL; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS, LDL; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0032535310     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00692-4     Document Type: Article

References (21)

1. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 7th ed. New York: McGraw-Hill, 1995:1981-2030.
2. Mabuchi H, Koizumi L, Shimizu M, Takeda R, and The Hokuriku FH-CHD Study Group. Development of coronary heart disease in familial hypercholesterolemia. Circulation 1989;79:225-232.
3. Mabuchi H, Sakai T, Sakai Y, Yoshimura A, Watanabe A, Wakasugi T, Koizumi J, Takeda R. Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine. N Engl J Med 1983;308:609-613.
4. Witztum JL, Simmons D, Steinberg D, Beltz WF, Weinreb R, Young SG, Lester P, Kelly N, Juliano J. Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydro chloride. Circulation 1989;79:16-28.
5. Yokoyama S, Hayashi R, Kikkawa T, Tani N, Takada S, Hatanaka K, Yamamoto A. Specific adsorbent of apolipoprotein-B-containing lipoproteins for plasmapheresis. Characterization and experimental use in hypercholesterolemic rabbits. Arteriosclerosis 1984;4:276-282.
6. Mabuchi H, Michishita I, Takeda M, Fujita H, Koizumi J, Takeda R, Takada S, Oonishi M. A new low density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL continuous apheresis). Atherosclerosis 1987;68:19-25.
7. Mabuchi H. Use of LDL-apheresis in the management of familial hypercholesterolemia. Curr Opin Lipidol 1990;l:43-47.
8. Stamler J, Wentworth D, Neaton J. Is the relationship between serum cholesterol and risk of death from CHD continuous and graded? JAMA 1986;256:2823-2828.
9. Mabuchi H, Ito S, Haba T, Ueda K, Tatami R, Kametani T, Koizumi J, Ohta M, Miyamoto S, Takeda R, Takegoshi T. Discrimination of familial hypercholesterolemia and secondary hypercholesterolemia by Achilles tendon thickness. Atherosclerosis 1977;28:61-68.
10. Allain CC, Pool IS, Chan SCG. Enzymatic determination of total serum cholesterol. Clin Chem 1974;20:470-475.
11. Sugiura M, Oikawa T, Hirano K, Maeda H, Yoshimura H, Sugiyama M, Kuratsu T. A simple colorimetric method for determination of serum triglycerides with lipoprotein lipase and glycerol dehydrogenase. Clin Chim Acta 1977;81:125-130.
12. + precipitation and enzymatic measurement. J Jpn Atheroscler Soc 1981;9:393-398.
13. Koizumi J, Koizumi I, Uno Y, Inazu A, Kajinami K, Haraki T, Yagi K, Kamon N, Miyamoto S, Takegoshi T, Mabuchi H, Takeda R, Tani N, Takada S. Reduction of lipoprotein (a) by LDL-apheresis using a dextran sulfate cellulose column in patients with familial hypercholesterolemia. Atherosclerosis 1993;100:65-74.
14. Thompson GR, Maher VM, Matthews S, Kitano Y, Neuwirth C, Shortt MB, Davies G, Rees A, Mir A, Prescott RJ, de Feyter P, Henderson A. Familial hypercholesterolemia regression study: a randomized trial of low-density-lipoprotein apheresis. Lancet 1995;345: 811-816.
15. Kroon AA, Aengevaeren WR, van der Werf T, Uijen GJ, Reiber JH, Bruschke AV, Stalenhoef AF. LDL-apheresis atherosclerosis regression study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996;93:1826-1835.
16. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
17. Rubba P, Iannuzzi A, Postiglione A, Scarpato N, Montefusco S, Gnasso A, Nappi G, Cortese C, Mancini M. Hemodynamic changes in the peripheral circulation after repeat low density lipoprotein apheresis in familial hypercholesterolemia. Circulation 1990;81:610-616.
18. Igarashi K, Horimoto M, Takenaka T, Inoue H, Miyata S. Acute cholesterol lowering therapy with LDL-apheresis improves endothelial function of the coronary microcirculation in patients with hypercholesterolemia. Circulation 1995;92(suppl I):I-452.
19. Mabuchi H, Fujita H, Michishita I, Takeda M, Kajinami K, Koizumi J, Takeda R, Takegoshi T, Wakasugi T, Ueda K, Miyamoto S, Watanabe A, Oota M. Effects of CS-514 (eptastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum lipid and apolipoprotein levels in heterozygous familial hypercholesterolemic patients treated by low density lipoprotein (LDL) apheresis. Atherosclerosis 1988;72:183-188.
20. Thompson GR, Miller JP, Breslow JL. Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange. Br Med J 1985;291:1671-1673.
21. Hennerici M, Kleophas W, Gries FA. Regression of carotid plaques during low density lipoprotein cholesterol elimination. Stroke 1991;22:989-992.